Melanotan II

Melanotan II is a synthetic melanocortin agonist studied for increased pigmentation, with measurable tanning in early human studies but meaningful safety concerns around dose escalation and skin monitoring.

Profile · 01

Overview

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-MSH that activates melanocortin receptors, especially MC1R and MC4R. It is not FDA-approved and has no broad regulatory approval from major agencies.

The source frames this as a loading-then-maintenance protocol centered on pigmentation goals. It also highlights the need for conservative dosing because nausea, flushing, mole changes, and higher-dose toxicity are real concerns rather than minor footnotes.

At a Glance

Goal
Support increased skin pigmentation through melanocortin receptor activation while managing dose-related risk
Categories
PigmentationTanningMelanocortin Agonist
Synergistic
Sunscreen · Vitamin D
Profile · 02

Protocol

Suggested daily loading approach followed by lower-frequency maintenance once the target pigmentation is reached.

Reconstitute
Add 3.0 mL bacteriostatic water to a 10 mg vial for about 3.33 mg/mL concentration
Typical daily range
250-1000 mcg daily during loading
Start
250 mcg daily for Week 1
Target
1000 mcg daily by Week 4, then 500-1000 mcg 1-2 times weekly for maintenance
Frequency
Daily during loading, then 1-2 times weekly for maintenance
Cycle Length
6-8 weeks loading phase, then maintenance as needed
Timing
Any consistent time; rotate injection sites
Route
Subcutaneous
Cycle
6-8 weeks loading, then maintenance as needed

Inject once daily during the loading phase and transition to maintenance dosing after the desired pigmentation is reached. The source specifically warns against aggressive dosing because toxicity reports exist at megadoses, and skin monitoring is part of the protocol rather than an optional extra.

Dose progression

Week 1
250 mcg (0.25 mg) · 7.5 units (0.075 mL)
Week 2
500 mcg (0.50 mg) · 15 units (0.15 mL)
Week 3
750 mcg (0.75 mg) · 22.5 units (0.225 mL)
Weeks 4-8
1000 mcg (1.0 mg) · 30 units (0.30 mL)
Maintenance
500-1000 mcg 1-2 times weekly · 15-30 units (0.15-0.30 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How Melanotan II works.

Melanotan II acts primarily through melanocortin receptors. MC1R activation on melanocytes increases melanin production and distribution, while MC4R activity helps explain non-pigmentation effects such as appetite suppression and erectile or libido-related changes discussed in the literature.

The source cites early human dosing work showing measurable tanning after several low-dose injections, but it also highlights meaningful safety concerns including nausea, flushing, mole changes, and severe toxicity at much higher doses. This is not a benign cosmetic entry.

Science · 02

Effects

Observations from clinical or preclinical literature.

Human studies and clinical reports support increased pigmentation with loading-style dosing
Maintenance dosing can help preserve pigmentation after the initial phase
MC4R activity may also produce libido or appetite effects in some users
Nausea is the most common dose-related side effect
Facial flushing, warmth, reduced appetite, or fatigue may occur
Pigmentation changes in existing moles require caution and dermatologic follow-up
Science · 03

Caution

Avoid in personal history of melanoma, atypical mole syndrome, or high skin-cancer risk
Not recommended during pregnancy or breastfeeding because safety data is insufficient
Use caution in cardiovascular conditions because higher doses may affect heart rate or blood pressure
Do not exceed conservative dosing ranges; megadose toxicity has been reported

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Sunscreen / UV protection
Critical because increased pigmentation does not eliminate UV damage risk.
Vitamin D
Useful to monitor when sun exposure patterns change.
Antioxidants
Vitamin C and vitamin E may support skin-health goals broadly.
Hydration and electrolytes
Helpful if nausea or appetite suppression occurs.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Use sun protection consistently even if pigmentation increases
Photograph skin and existing moles under consistent lighting for trend tracking
Maintain hydration, especially if nausea or reduced appetite occurs
Stay conservative with dose escalation because faster is not safer here
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Skin pigmentation changes - use consistent photos to judge response rather than guesswork
  2. Mole changes - document size, border, or color changes and seek evaluation if concerning
  3. Nausea and appetite - useful for titration decisions
  4. Blood pressure and heart rate - especially relevant during escalation
  5. Injection-site reactions - note redness, swelling, or discomfort
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Dermatologic skin exam
Baseline and follow-up skin review is more important here than most peptide pages.
CBC (Complete Blood Count)
General safety and baseline context.
CMP (Comprehensive Metabolic Panel)
Assesses liver and kidney function during the protocol.
CK (Creatine Kinase)
Reasonable if toxicity or severe systemic symptoms are a concern.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry fully
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites across the abdomen, thighs, and upper arms to reduce local irritation
Discard used syringes immediately in a sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile insulin syringe for each injection and dispose of it safely
Inspect moles and skin regularly; new or changing lesions warrant prompt dermatologic review
Do not exceed conservative ranges because higher-dose toxicity reports exist
This peptide is not approved by major regulators and should be approached cautiously
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. PubMed
    Phase I clinical study of Melanotan II dosing and safety in healthy volunteers.
    https://pubmed.ncbi.nlm.nih.gov/8637402/
  2. DermNet NZ
    Clinical dermatology overview of Melanotan II effects and risks.
    https://dermnetnz.org/topics/melanotan-ii
  3. PubMed
    Case report of Melanotan II-associated systemic toxicity and rhabdomyolysis.
    https://pubmed.ncbi.nlm.nih.gov/23121206/
  4. International Peptide Society
    Melanotan II monograph covering dosing and titration discussion.
    https://peptidesociety.org/wp-content/uploads/2018/05/Melanotan-II-monograph-v2.docx.pdf
  5. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
On this page